NEW YORK (GenomeWeb News) – The Federation of American Societies for Experimental Biology has given its annual Public Service Award to Raynard Kington, who is principal deputy director of the National Institutes of Health and who was acting director at NIH before the appointment of Francis Collins to the director's post.
FASEB gave Kington the award particularly because of his administration of the American Recovery and Reinvestment Act funding, for the promotion of workforce diversity and for starting a conversation about "changing the fundamental business model of the biomedical enterprise," FASEB said.
"Raynard Kington explained the new and unprecedented [ARRA] program to the extramural community and mobilized the entire NIH staff, who worked heroically to respond to the new mandates, develop new programs, review tens of thousands of new applications, make thousands of awards, and surmount new regulatory hurdles," FASEB President Mark Lively said in a statement.
Myriad Genetics has elected Heiner Dreismann to serve on its board of directors. Dreismann spent two decades at Roche and served as president and CEO of Roche Molecular Systems, and he currently serves on the boards of several health care companies.
Response Genetics has named Michael McNulty as a its new COO. McNulty joins the firm from Agilent Technologies, where he most recently served as general manager of diagnostics. He also previously served as VP of laboratory operations at Berkeley HeartLab.
Transgenomic Chief Financial Officer Debra Schneider has submitted her resignation from that position, the company stated in a recent filing with the US Securities and Exchange Commission. Transgenomic has not yet named a replacement for Schneider, who leaves the company as of June 16.
StemCells has appointed R. Scott Greer to serve on its board of directors. Greer is currently a principal and managing director of Numenor Ventures, and he previously founded the therapeutic antibody company Abgenix. Greer also has held senior management positions at Cell Genesys and he worked in various jobs at Genetics Institute, which was acquired by Wyeth.
CombiMatrix has named Mark McGowan to chair its board of directors. McGowan replaces outgoing chairman Tom Akin.
Additionally, Brooke Anderson has resigned from CombiMatrix's board, and will step down from his post as chief operating officer upon the closure of the company's facilities in Mukilteo, Wash.
Board director Rigdon Currie has been appointed chairman of CombiMatrix's audit committee, and will retain his role as chairman of the compensation committee, the company said. Board Director Scott Gottlieb has also been appointed a member of the audit committee.
Genstruct has appointed David de Graaf as its chief scientific officer. De Graaf most recently served as vice president of biotherapeutics and integrative biology at Boehringer-Ingelheim. Prior to that, he was director of systems biology at Pfizer and built the first systems biology team at AstraZeneca.
Before his career in industry, de Graaf was a researcher at the Weizmann Institute of Science and the Center for Genome Research at Whitehead/MIT.
Pathogenica, a genomics start-up focused on pathogen detection technologies, said today that George Church and Ronald Davis have joined its scientific advisory board.
The Cambridge, Mass.-based firm plans to develop commercial applications for pathogen sequencing and technologies for rapid, multiplex identification of pathogens, drug-resistant genes, and toxins in patient samples.
Church is director of the Center for Computational Genetics, a founder of the human genome sequencing firm Knome, and he serves on the advisory boards at a number of biomedical research companies.
Ronald Davis is director of the Stanford Genome Technology Center, he is a co-founder of the company ParAllele, which was acquired by Affymetrix, and he has been involved in starting or spinning off multiple companies involved in genomics.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.